Calidad de vida en pacientes tratados con metadona: el WHOQOL-BREF, estudio psicométrico y resultados de aplicación / Quality of life in patients treated with methadone: The WHOQOLBREF, psychometric study and application results

Objetivo. De entre los muchos instrumentos propuestos para medir la calidad de vida de los pacientes con adicción a opiáceos tratados con metadona el WHOQOL-BREF, propuesto por la World Health Organization, es el que más se utiliza en la actualidad. Este trabajo pretende estudiar la fiabilidad y la validez de constructo de la prueba, aplicada a una muestra amplia y representativa de pacientes, y comparar los resultados con los datos disponibles para población general en España. Se reclutó una muestra de 523 sujetos que se encontraban en tratamiento con metadona, en Madrid y Extremadura. Se efectuó un análisis factorial confirmatorio para probar la estructura teóricamente propuesta y, seguidamente, un análisis paralelo optimizado para conocer el número más adecuado de componentes de la prueba. Los resultados muestran que la prueba presenta sólidos valores de consistencia interna, tanto a nivel del ítem como de las escalas. La estructura tetradimensional teórica se confirma en la muestra con adecuados indicadores de ajuste, aunque también se obtienen serios argumentos para considerar su unidimensionalidad. Se estudió la relación estructural entre los cuatro dominios. El WHOQOL-BREF se muestra como una prueba fiable y válida para su uso en pacientes tratados con metadona, proporcionando una medida multidimensional de la calidad de vida percibida, que incluye factores sociales y ambientales ausentes en otros instrumentos, que son de enorme importancia en el tratamiento de los problemas adictivos

The most commonly instrument used to measure quality of life in patients with addictive behaviors is the WHOQOL-BREF, developed by the World Health Organization. No studies have been found to explore the psychometric properties in Spanish clinical samples. This paper aims to study their reliability as well as the construct validity in a representative sample of patients and comparing the results to the data available for the general population in Spain. A sample was recruited comprised of 523 subjects who were undergoing treatment with methadone in Madrid and Extremadura. A confirmatory factor analysis was completed to test the theoretically proposed structure and then an optimized-parallel analysis was done to establish the most adequate number of components. The result offers solid values for internal consistency both as concerns the items and the scales. The theoretical tetra-dimensional structure is confirmed in the sample although serious arguments are also found for considering its onedimensionality. The structural relationship between the four domains was studied. The WHOQOL-BREF proves to be a reliable and valid test for use on patients treated with methadone, providing a multi-dimensional measure of perceived quality of life that includes social and environmental factors of great importance in treating addiction problems

Inhibidores del cotransportador sodio-glucosa tipo 2(SGLT2): de la glucosuria renal familiar al tratamiento de la diabetes mellitus tipo 2 / Sodium-glucose cotransporter type 2 inhibitors (SGLT2): from familial renal glycosuria to the treatment of type 2 diabetes mellitus

Durante siglos, el riñón se ha considerado principalmente un órgano de eliminación y un regulador de la sal y del equilibrio iónico. A pesar de que una vez se pensó que era la causa estructural de la diabetes, y que en los últimos años ha sido ignorado como regulador de la homeostasis de la glucosa, actualmente es reconocido como un actor importante en el ámbito de la regulación del metabolismo glucídico. Durante el ayuno, el 55% de la glucosa proviene de la gluconeogénesis. Sólo 2 órganos tienen esta capacidad: el hígado y el riñón. Este último es responsable del 20% de la producción total deglucosa y del 40% de la producida por la gluconeogénesis. Hoy en día tenemos una mejor comprensión de la fisiología del transporte de glucosa renal a través de transportadores específicos, como el cotransportador sodio-glucosa tipo 2(SGLT2 por sus siglas en inglés: Sodium Glucose Cotransporter). Un compuesto natural, floricina, se aisló a principios de1800 y durante décadas desempeñó un papel importante enla diabetes y la investigación de la fisiología renal. Finalmente, en el nexo de estos descubrimientos antes mencionados, se reconoció el efecto de compuestos floricina-like en los transportadores de glucosa renal, lo que ha ofrecido un nuevo mecanismo para el tratamiento de la hiperglucemia. Esto ha llevado al desarrollo de varias modalidades terapéuticas potencialmente eficaces para el tratamiento de la diabetes (AU)

For centuries, the kidney has been considered primarily an organ of elimination and a regulator of salt and ion balance. Although once thought that the kidney was the structural cause of diabetes, which in recent years has been ignored as a regulator of glucose homeostasis, is now recognized as a major player in the field of metabolic regulation carbohydrate. During fasting, 55% of the glucose comes from gluconeogenesis. Only 2 organs have this capability: the liver and kidney. The latter is responsible for 20% of total glucose production and 40%of that produced by gluconeogenesis. Today we have a better understanding of the physiology of renal glucose transport via specific transporters, such as type 2 sodiumglucose cotransporter (SGLT2). A natural compound, phlorizin, was isolated in early 1800 and for decades played an important role in diabetes and renal physiology research. Finally, at the nexus of these findings mentioned above, recognized the effect of phlorizin-like compounds in the renal glucose transporter, which has offered a new mechanism to treat hyperglycemia. This has led to the development of several potentially effective treatment modalities for the treatment of diabetes (AU)

[Sodium-glucose cotransporter type 2 inhibitors (SGLT2): from familial renal glucosuria to the treatment of type 2 diabetes mellitus]. / Inhibidores del cotransportador sodio-glucosa tipo 2 (SGLT2): de la glucosuria renal familiar al tratamiento de la diabetes mellitus tipo 2.

For centuries, the kidney has been considered primarily an organ of elimination and a regulator of salt and ion balance. Although once thought that the kidney was the structural cause of diabetes, which in recent years has been ignored as a regulator of glucose homeostasis, is now recognized as a major player in the field of metabolic regulation carbohydrate. During fasting, 55% of the glucose comes from gluconeogenesis. Only 2 organs have this capability: the liver and kidney. The latter is responsible for 20% of total glucose production and 40% of that produced by gluconeogenesis. Today we have a better understanding of the physiology of renal glucose transport via specific transporters, such as type 2 sodium-glucose cotransporter  (SGLT2). A natural compound, phlorizin, was isolated in early 1800 and for decades played an important role in diabetes and renal physiology research. Finally, at the nexus of these findings mentioned above, recognized the effect of phlorizin-like compounds in the renal glucose transporter, which has offered a new mechanism to treat hyperglycemia. This has led to the development of several potentially effective treatment modalities for the treatment of diabetes.

Tratamiento del hipogonadismo hipogonadotropo femenino / No disponible

No disponible

[Prinzmetal's angina]. / Angina de Prinzmetal.

We have described a coronary ischemic syndrome not infrequent. It has been diagnosed only a few times in our medium and it can cause grave risks for the patient if it is not recognized in time and managed in an adequate manner.